GO:0015216 purine nucleotide transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015216 describes the molecular function of moving purine nucleotides such as ATP, ADP, AMP, GTP, GDP, and GMP across biological membranes.
• The function is essential for nucleotide homeostasis, purinergic signaling, and energy transfer between cellular compartments [1,4].
• Key proteins with this activity include CFTR, which can transport ATP and other nucleotides, as well as members of the SLC and ABC transporter families [1,4,6].
• Dysregulation of purine nucleotide transport is linked to cystic fibrosis, cancer, and metabolic disorders [1,3,7].
• CRISPR knockout, point-mutation, and knock-in models are powerful tools to dissect the physiological roles of these transporters [7,8].
• EDITGENE provides end-to-end services for generating and screening cell models to study purine nucleotide transmembrane transporter activity [7,8].
Description
Purine nucleotide transmembrane transporter activity (GO:0015216) is a molecular function that enables the transfer of purine nucleotides, such as ATP, ADP, AMP, GTP, GDP, and GMP, from one side of a membrane to the other. This activity is fundamental to cellular processes including energy metabolism, signal transduction, and nucleic acid synthesis. Researchers study this term to understand how nucleotides are compartmentalized and how their transport influences physiology and disease [1,4]. The cystic fibrosis transmembrane conductance regulator (CFTR) is a well-characterized example of a protein that can transport ATP and other nucleotides, and its function is modulated by glutamate and ATP. Other transporters, such as those in the SLC family, also contribute to purine nucleotide transport across membranes. Understanding GO:0015216 is critical for deciphering mechanisms of purinergic signaling, epithelial secretion, and metabolic regulation [1,3,7].
purine nucleotide transmembrane transporter activity At A Glance
| GO ID | GO:0015216 |
|---|---|
| GO term | purine nucleotide transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Enables the transfer of a purine nucleotide, any compound consisting of a purine nucleoside esterified with (ortho)phosphate, from one side of a membrane to the other. |
| Major function | Transport of purine nucleotides across membranes |
| Substrates | ATP, ADP, AMP, GTP, GDP, GMP |
| Cellular location | Integral membrane proteins (plasma membrane, organelle membranes) |
| Related diseases | Cystic fibrosis, cancer, metabolic disorders |
What Is GO:0015216?
In simple terms, GO:0015216 is the activity that moves purine nucleotides across a membrane. According to QuickGO, it enables the transfer of a purine nucleotide, any compound consisting of a purine nucleoside esterified with (ortho)phosphate, from one side of a membrane to the other. This includes molecules like ATP, ADP, AMP, GTP, GDP, and GMP. The activity is typically mediated by integral membrane proteins that form channels or transporters, and it is distinct from purine nucleoside transport (which involves nucleosides without phosphate groups).
Why Is purine nucleotide transmembrane transporter activity Important in Cell Biology?
Purine nucleotide transmembrane transporter activity is vital for maintaining cellular nucleotide pools, facilitating energy transfer between compartments, and enabling purinergic signaling. Dysfunction of these transporters can lead to impaired epithelial secretion, altered immune responses, and metabolic imbalances. For example, CFTR, which exhibits ATP transport activity, is mutated in cystic fibrosis, a disease characterized by defective chloride and bicarbonate transport [1,3]. Additionally, nucleotide transporters are implicated in cancer progression and chemoresistance, making them attractive therapeutic targets. Studying this activity helps researchers understand fundamental membrane biology and develop interventions for related diseases.
• Maintains intracellular and extracellular nucleotide homeostasis.
• Enables purinergic signaling by releasing ATP for receptor activation.
• Supports epithelial fluid and electrolyte secretion.
• Contributes to energy transfer across mitochondrial and other organelle membranes.
• Plays a role in drug resistance by transporting nucleotide analogs.
• Involved in immune cell activation and inflammation.
• Linked to cystic fibrosis and other channelopathies [1,3].
• Potential target for cancer therapy.
• Essential for nucleotide salvage and recycling pathways.
• Provides a model for studying membrane protein structure-function.
What Happens During purine nucleotide transmembrane transporter activity?
Substrate Recognition and Binding
In simple terms: The transporter first grabs the purine nucleotide it will move.
The transporter protein has a binding site that specifically recognizes purine nucleotides such as ATP or GTP. This binding is often dependent on the presence of specific ions or cofactors. For CFTR, nucleotide binding to its nucleotide-binding domains (NBDs) is a prerequisite for its transport function, and this binding can be modulated by glutamate and ATP. The first nucleotide-binding fold of CFTR targets the membrane and retains ATP binding function.
Conformational Change and Translocation
In simple terms: The transporter changes shape to push the nucleotide across the membrane.
Upon nucleotide binding, the transporter undergoes conformational changes that move the substrate across the lipid bilayer. This process may involve alternating access mechanisms. For CFTR, ATP binding and hydrolysis at the NBDs regulate channel gating, and the protein can also catalyze adenylate kinase activity, which may influence nucleotide transport. The dynamic selectivity of CFTR for nucleotides is controlled by glutamate and ATP.
Release and Reset
In simple terms: The nucleotide is released on the other side, and the transporter resets.
After translocation, the nucleotide is released into the target compartment, and the transporter returns to its initial state. This cycle requires energy input or concentration gradients. In epithelial cells, CFTR-mediated ATP transport contributes to luminal ATP pools that activate purinergic receptors. The process is tightly regulated to prevent excessive nucleotide loss.
Regulation by Cellular Signals
In simple terms: Other molecules can turn the transporter on or off.
The activity of purine nucleotide transporters is regulated by various signals, including calcium, cAMP, and protein-protein interactions. For instance, store-independent activation of STIM1-ORAI1 by SPCA2 determines basal CFTR activity in secretory epithelial cells, linking calcium signaling to nucleotide transport. Additionally, SLC33A1-dependent Golgi sialic acid O-acetylation can influence membrane protein function, potentially affecting transporter activity.
Key Genes Involved in GO:0015216 purine nucleotide transmembrane transporter activity
The following genes encode proteins that exhibit or regulate purine nucleotide transmembrane transporter activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CFTR | ATP and nucleotide transport; chloride channel | Cystic fibrosis; epithelial secretion [1,3] |
| SLC33A1 | Golgi sialic acid O-acetylation; indirect role | CASD1 catalysis; Golgi function |
| STIM1 | Calcium sensor; regulates CFTR activity | Store-independent activation |
| ORAI1 | Calcium channel; regulates CFTR activity | Basal CFTR activity |
| SPCA2 | Calcium pump; regulates STIM1-ORAI1 | Secretory epithelial cells |
| ATP1A1 | Na,K-ATPase; maintains ion gradients | Indirectly affects nucleotide transport |
| ATP1B1 | Na,K-ATPase subunit | Ion gradient maintenance |
| ABCC7 | CFTR gene alias | ABC transporter family |
| NBD1 | CFTR nucleotide-binding domain 1 | ATP binding and membrane targeting |
| NBD2 | CFTR nucleotide-binding domain 2 | ATP hydrolysis and gating |
| CASD1 | Sialic acid O-acetylation | Golgi function; indirect |
| SLC25A | Mitochondrial nucleotide transporters | Energy transfer |
| ENT1 | Equilibrative nucleoside transporter | Nucleoside transport (related) |
| CNT | Concentrative nucleoside transporter | Nucleoside transport (related) |
| P2X | Purinergic receptors | ATP signaling |
| P2Y | Purinergic receptors | ATP signaling |
| AK | Adenylate kinase | Nucleotide metabolism |
How Is purine nucleotide transmembrane transporter activity Regulated?
The activity of purine nucleotide transmembrane transporters is regulated at multiple levels. CFTR, a key protein with this activity, is regulated by phosphorylation via PKA and by ATP binding and hydrolysis at its nucleotide-binding domains [1,4]. Glutamate and ATP dynamically control CFTR selectivity. Calcium signaling through STIM1-ORAI1 and SPCA2 modulates basal CFTR activity in secretory epithelial cells. Additionally, post-translational modifications such as sialic acid O-acetylation in the Golgi can influence membrane protein function, potentially affecting transporter activity. Ion gradients maintained by Na,K-ATPase also indirectly regulate nucleotide transport.
purine nucleotide transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CFTR | Cystic fibrosis | Knockout and point-mutation cell models [1,3] |
| SLC33A1 | Golgi dysfunction; CASD1 catalysis | Knockout and overexpression models |
| STIM1 | Immune disorders; calcium signaling | Knock-in and knockout models |
| ORAI1 | Immunodeficiency | Point-mutation models |
| SPCA2 | Secretory epithelial dysfunction | Overexpression models |
Cystic Fibrosis
Mutations in CFTR, which exhibits purine nucleotide transmembrane transporter activity, cause cystic fibrosis. CFTR transports ATP and other nucleotides, and its dysfunction leads to defective chloride and bicarbonate secretion, resulting in thick mucus and chronic infections [1,3]. Studies have shown that CFTR can be addressed to the apical domain of polarized cells, and its nucleotide transport function is critical for epithelial homeostasis.
Cancer
Purine nucleotide transporters are often upregulated in cancer cells to support rapid proliferation and drug resistance. They can transport nucleotide analogs used in chemotherapy, affecting treatment efficacy. Targeting these transporters may sensitize tumors to therapy.
Metabolic Disorders
Dysregulation of nucleotide transport can lead to metabolic imbalances, affecting energy homeostasis and signaling. For example, mitochondrial nucleotide transporters are essential for oxidative phosphorylation and their defects can cause mitochondrial diseases.
From purine nucleotide transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CFTR transport ATP in epithelial cells? | CFTR knockout and point-mutation cell lines [1,5] |
| How does SLC33A1 affect Golgi function? | SLC33A1 knockout and overexpression models |
| What is the role of STIM1-ORAI1 in CFTR activity? | STIM1/ORAI1 knockout and knock-in models |
| Can purine nucleotide transporters be targeted in cancer? | Overexpression and knockout cancer cell lines |
| How does Na,K-ATPase regulate nucleotide gradients? | ATP1A1 point-mutation models |
| What is the structural basis of nucleotide binding? | Tagged knock-in for imaging |
How to Study the purine nucleotide transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive uptake | Nucleotide transport rate | Quantify transporter activity |
| Patch-clamp | Ion currents | CFTR channel function [1,3] |
| Ussing chamber | Transepithelial transport | Epithelial secretion |
| Fluorescence microscopy | Protein localization | Trafficking studies |
| ATPase assay | ATP hydrolysis | NBD function |
| Adenylate kinase assay | Nucleotide interconversion | CFTR catalytic activity |
| Site-directed mutagenesis | Structure-function relationships | Point-mutation analysis |
Transport Assays
Radioactive or fluorescent nucleotide uptake assays measure the rate of purine nucleotide transport across membranes. These assays can be performed in cell lines expressing wild-type or mutant transporters to assess activity.
Electrophysiology
Patch-clamp and Ussing chamber techniques measure ion currents associated with nucleotide transport, particularly for CFTR. These methods reveal channel gating and selectivity [1,3].
Imaging and Localization
Fluorescence microscopy with tagged transporters (e.g., VSV epitope) visualizes subcellular localization and trafficking in polarized cells.
Biochemical Assays
ATPase and adenylate kinase assays measure nucleotide hydrolysis and interconversion, providing insights into the catalytic mechanism of transporters like CFTR.
How CRISPR Can Be Used to Study GO:0015216 purine nucleotide transmembrane transporter activity
Knockout
CRISPR knockout of genes encoding purine nucleotide transporters (e.g., CFTR, SLC33A1) creates cell models to study loss-of-function phenotypes, such as impaired nucleotide transport and downstream signaling [7,8].
Point Mutation
Introducing disease-associated point mutations (e.g., CFTR F508del) via CRISPR allows researchers to dissect the molecular defects in transporter function and trafficking [1,6].
Knock-in
Knock-in of tagged or reporter versions of transporters enables real-time imaging and biochemical purification, facilitating studies of localization and interactions.
Overexpression
CRISPR activation or cDNA overexpression of transporters can amplify transport activity, useful for structural and pharmacological studies.
How EDITGENE Supports purine nucleotide transmembrane transporter activity Research
Researchers studying purine nucleotide transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in nucleotide transport, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for purine nucleotide transmembrane transporter activity research.
Frequently Asked Questions About purine nucleotide transmembrane transporter activity
What is GO:0015216?
GO:0015216 is the Gene Ontology term for purine nucleotide transmembrane transporter activity, which enables the transfer of purine nucleotides like ATP and GTP across membranes.
What genes are involved in purine nucleotide transmembrane transporter activity?
Key genes include CFTR, SLC33A1, STIM1, ORAI1, and SPCA2, among others [1,7,8].
How is purine nucleotide transport regulated?
It is regulated by ATP binding, phosphorylation, calcium signaling, and protein interactions [1,4,7].
What diseases are associated with defective purine nucleotide transport?
Cystic fibrosis, cancer, and metabolic disorders are linked to dysfunction in these transporters [1,3,7].
What methods are used to study purine nucleotide transmembrane transporter activity?
Common methods include radioactive uptake assays, patch-clamp, Ussing chamber, and fluorescence microscopy [1,3,5].
Can CRISPR be used to study purine nucleotide transporters?
Yes, CRISPR knockout, point mutation, and knock-in models are widely used to dissect transporter function [7,8].
What is the role of CFTR in purine nucleotide transport?
CFTR can transport ATP and other nucleotides, and this activity is modulated by glutamate and ATP.
How does SLC33A1 relate to purine nucleotide transport?
SLC33A1 is involved in Golgi sialic acid O-acetylation, which can indirectly affect membrane protein function, including transporters.
What cell models are available for studying purine nucleotide transport?
Knockout, point-mutation, knock-in, and overexpression cell models can be generated using CRISPR [7,8].
Why is purine nucleotide transmembrane transporter activity important?
It maintains nucleotide homeostasis, supports energy transfer, and enables purinergic signaling, with implications for many diseases [1,4].
Conclusion
Purine nucleotide transmembrane transporter activity (GO:0015216) is a fundamental molecular function that governs the movement of ATP, GTP, and related nucleotides across cellular membranes. Its dysregulation is implicated in cystic fibrosis, cancer, and metabolic disorders. By leveraging CRISPR-based cell models and advanced screening technologies, researchers can uncover new insights into the mechanisms and therapeutic potential of these transporters. EDITGENE is committed to supporting this research with tailored gene editing and bioinformatics services.
References
- 1. Reddy MM et al.. 2003. Control of dynamic CFTR selectivity by glutamate and ATP in epithelial cells.. Nature 423(6941):756-60 PMID: 12802335
- 2. Kaplan JH. 2002. Biochemistry of Na,K-ATPase.. Annu Rev Biochem 71:511-35 PMID: 12045105
- 3. Namkung W et al.. 2003. Ca2+ activates cystic fibrosis transmembrane conductance regulator- and Cl- -dependent HCO3 transport in pancreatic duct cells.. J Biol Chem 278(1):200-7 PMID: 12409301
- 4. Gross CH et al.. 2006. Nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator, an ABC transporter, catalyze adenylate kinase activity but not ATP hydrolysis.. J Biol Chem 281(7):4058-68 PMID: 16361259
- 5. Costa de Beauregard MA et al.. 2000. Functional cystic fibrosis transmembrane conductance regulator tagged with an epitope of the vesicular stomatis virus glycoprotein can be addressed to the apical domain of polarized cells.. Eur J Cell Biol 79(11):795-802 PMID: 11139142
- 6. Ko YH et al.. 1997. Cystic fibrosis transmembrane conductance regulator: the first nucleotide binding fold targets the membrane with retention of its ATP binding function.. Biochemistry 36(16):5053-64 PMID: 9125527
- 7. Kiss AK et al.. 2025. Store-independent activation of STIM1-ORAI1 by SPCA2 determines the basal CFTR activity in secretory epithelial cells.. Curr Biol 35(20):4970-4987.e7 PMID: 41015040
- 8. Albers M et al.. 2026. Interplay of SLC33A1-dependent and -independent Golgi sialic acid O-acetylation in CASD1 catalysis.. Nat Commun 17(1) PMID: 41917001
